 | Up a level |
2021
Graeser, Monika 
ORCID: 0000-0003-1916-717X, Harbeck, Nadia, Gluz, Oleg, Wuerstlein, Rachel, zu Eulenburg, Christine, Schumacher, Claudia, Grischke, Eva -Maria, Forstbauer, Helmut, Dimpfl, Moritz ORCID: 0000-0001-6202-7397, Braun, Michael, Christgen, Matthias, Kreipe, Hans Heinrich, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Kuemmel, Sherko ORCID: 0000-0001-9355-494X and Nitz, Ulrike
(2021).
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials.
Breast, 59.
S. 58 - 67.
EDINBURGH:
CHURCHILL LIVINGSTONE.
ISSN 1532-3080
Graeser, Monika ORCID: 0000-0003-1916-717X, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Herzog, Christopher, Umutlu, Lale, Frydrychowicz, Alex, Rjosk-Dendorfer, Dorothea, Wuerstlein, Rachel, Culemann, Ralph, Eulenburg, Christine, Adams, Jascha, Nitzsche, Henrik, Prange, Anna, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Kolberg-Liedtke, Cornelia, Harbeck, Nadia, Kuhl, Christiane K. and Nitz, Ulrike
(2021).
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
Breast Cancer Res., 23 (1).
LONDON:
BMC.
ISSN 1465-542X
Harbeck, Nadia ORCID: 0000-0002-9744-7372, von Schumann, Raquel, Kates, Ronald Ernest, Braun, Michael, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Forstbauer, Helmut, Tio, Joke, Grischke, Eva-Maria, Biehl, Claudia, Liedtke, Cornelia, De Haas, Sanne Lysbet, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Gluz, Oleg
(2021).
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Cancers, 13 (19).
BASEL:
MDPI.
ISSN 2072-6694
Wuerstlein, Rachel, Harbeck, Nadia, Grischke, Eva-Maria, Forstmeyer, Dirk, von Schumann, Raquel, Krabisch, Petra, Ludtke-Heckenkamp, Kerstin, Stefek, Andrea, Stoetzer, Oliver, Grafe, Andrea, Kaltenecker, Gabriele, Forstbauer, Helmut, Augustin, Doris, Schrader, Iris, Tio, Joke, Nitz, Ulrike, Gluz, Oleg, Kates, Ronald E. and Graeser, Monika Karla (2021). Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients. Breast Care, 16 (1). S. 50 - 59. BASEL: KARGER. ISSN 1661-3805
2018
Gluz, Oleg, Nitz, Ulrike, Liedtke, Cornelia, Christgen, Matthias, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Bangemann, Nikola, Lindner, Christoph, Kuemmel, Sherko, Clemens, Michael, Potenberg, Jochem, Staib, Peter, Kohls, Andreas, von Schumann, Raquel and Harbeck, Nadia (2018). Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. JNCI-J. Natl. Cancer Inst., 110 (6). S. 628 - 638. CARY: OXFORD UNIV PRESS INC. ISSN 1460-2105
2017
Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kates, Ronald Ernest, Braun, Michael, Kueemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Kraemer, Stefan, Kleine-Tebbe, Anke, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, von Schumann, Raquel, Liedtke, Cornelia, Grischke, Eva-Maria, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Nitz, Ulrike Anneliese (2017). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J. Clin. Oncol., 35 (26). S. 3046 - 3057. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755